Robert Ballotti

8PUBLICATIONS
49CO-AUTHORS
Predictive and prognostic markersMolecular targetsGene and molecular therapyMetabolic medicineBiologically active molecules
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Aug 14, 2026
MICAL2 as a key effector of β-catenin signaling driving melanoma progression and therapeutic resistance.

|Jun 13, 2024
AMBRA1 levels predict resistance to MAPK inhibitors in melanoma.

Luca Di Leo, Chiara Pagliuca, Ali Kishk

|Nov 15, 2023
LKB1-SIK2 loss drives uveal melanoma proliferation and hypersensitivity to SLC8A1 and ROS inhibition.

Sarah Proteau, Imène Krossa, Chrystel Husser

|Apr 03, 2021
Methiothepin Increases Chemotherapy Efficacy against Resistant Melanoma Cells.

Nelly Durand, Méliné Simsir, Laurie Signetti

|Jan 19, 2021
Single-cell RNA sequencing reveals intratumoral heterogeneity in primary uveal melanomas and identifies HES6 as a driver of the metastatic disease.

Charlotte Pandiani, Thomas Strub, Nicolas Nottet

|Jan 19, 2021
FBXO32 links ubiquitination to epigenetic reprograming of melanoma cells.

Nadia Habel, Najla El-Hachem, Frédéric Soysouvanh

Pageof 2

Frequent Collaborators

3 joint publications

Guillaume Beranger

2 joint publications

Nicolas Macagno

2 joint publications

Caroline Gaudy-Marqueste

2 joint publications

Sacha Nahon-Estève